KYMR
Kymera TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The post-earnings bull read is that Q1 reinforced balance-sheet durability and platform breadth: cash, cash equivalents and investments were $1.55 billion at March 31, 2026 with runway into 2029, KT-579 entered Phase 1, and Gilead’s exercised KT-200 option adds a $45 million milestone [#8-K-2026-04-30]. Secondary coverage also framed the quarter as better than expected, with Zacks reporting EPS of -$0.71 versus a -$0.89 consensus and revenue above expectations.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +3.9.
What can break
KT-579 is only in Phase 1 healthy volunteers, so the program still faces classic early-stage safety, pharmacodynamic, and translation risk [#8-K-2026-04-30].
Momentum
40
Value
41
Sentiment
74
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $90.00 · Bull $115.00 · Bear $62.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $119.71
Why
Momentum40 · Δ7d -6.6
Value41 · Δ7d +0.1
Sentiment74 · Δ7d +3.9
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
40
34% active weight
Current posture
7d trendSoftening
Δ7d
-6.6
Δ21d
-19.3
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
74
33% active weight
Current posture
7d trendImproving
Δ7d
+3.9
Δ21d
+16.1
Why this grade
Composite grade C. Momentum 40.2 / Value 41.1 / Sentiment 74.4
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$6.45B
Beta
2.22
Shares Out
79.79M
P/E (TTM) · Derived
-22.0
P/S (TTM)
132.11
P/FCF (TTM) · Derived
-28.82
Rev YoY
-26.1%
EPS YoY
-14.7%
Gross Margin
-
Op Margin
-759.7%
Net Debt
-$485M
Current Ratio
7.38
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology